Introduction
Esophageal cancer is one of the most malignant types of cancer, with an estimated 600,000 new cases and 540,000 deaths
worldwide in 2020 [1]. Due to the fact that early esophageal carcinomas lack obvious symptoms, detection often occurs at a later
stage, with nearly half of all patients developing distant metastasis within five years of diagnosis [2]. Esophageal cancer is the
eighth most commonly diagnosed cancer and the sixth leading
cause of cancer death on a global scale [3].
As the cancer advances, complications include bleeding, pain,
and obstruction of the esophagus by the tumor. This can make it
difficult for food and liquid to pass through the esophagus into the
stomach for digestion. Patients with esophageal cancer often face
an elevated risk of malnutrition stemming from complications
such as nausea and vomiting, pain, dysphagia, and dyspepsia. Additionally, various treatment interventions like surgical resections
further contribute to the susceptibility of these patients to malnutrition and hinder their postoperative recovery [4]. Hence, the
significance of nutrition becomes paramount in this patient population. Consequently, ensuring adequate nutrition without jeopardizing hospital outcomes poses a crucial and challenging task
for healthcare providers caring for hospitalized cancer patients.
Since enteral nutrition bypasses the esophagus and delivers
nutrients directly into the stomach or small intestine, this form
of artificial nutrition can promote unobstructed healing in the
esophagus post-treatment. Enteral nutrition can maintain the
function and integrity of the gut barrier and has been associated
with increased protection against airway infections (as a result of
increased immunoglobulin A production.) However, enteral nutrition is often disturbed by diagnostic interventions and patient
care such as respiratory support, which may affect its capacity to
maintain nutritional goals [5].
Parenteral nutrition is unphysiological in nature this form of
nutrition bypasses the gastrointestinal tract and portal venous
system altogether and can provide nutritional support in an “allin-one” system with no further intervention needed. While this
lack of disturbance, compared to enteral nutrition, has its benefits, it is important to note that parenteral nutrition can increase
the risk of overfeeding and poses an increased susceptibility to
catheter-related bloodstream infections [5].
Several comprehensive studies have explored the diverse
modes of nutrition following surgical resection in esophageal cancer patients. However, there remains a scarcity of data regarding
the specific nutritional methods utilized by these patients, their
associated complications, and their potential impact on outcomes
for hospitalized esophageal cancer patients, irrespective of treatment modality (including radiotherapy, chemotherapy, or surgical
resection). Our study seeks to thoroughly explore the overall influence of various nutrition modes (enteral vs. parenteral) among
hospitalized esophageal cancer patients.
Materials and methods
Data design and source: This research utilized the National
Inpatient Sample for 2019-2020, a comprehensive database on
inpatient care across the United States. It is the largest publicly
available database, covering over 21 million hospital admissions
with an annual sample size ranging from 7 to 8 million. Notably, t represents a strict 20% sample of all hospital admissions in
the country, excluding entries related to rehabilitation and federal hospitals like Veterans Affairs hospitals. This dataset covers
data from 46 states plus the District of Columbia and includes
approximately 98% coverage of the U.S. population. Managed
by the Agency for Healthcare Research and Quality through the
Healthcare Costs and Utilization Project, this resource enables
analysis of diverse healthcare phenomena due to its large sample
size comprising around 8 million hospital stays annually, making
it suitable for generating national estimates and examining rare
diseases in depth.
Study population: The study analyzed the discharge data of
adult patients aged 18 and above diagnosed with esophageal
cancer in the NIS database using the ICD-10-Clinical Modification/Procedure Coding System (ICD-10-CM/PCS). The participants
were then divided into enteral and parenteral nutrition groups.
Study variables and outcomes: The study aimed to compare
the effects of enteral and parenteral nutrition on outcomes in hospitalized patients diagnosed with esophageal cancer. The primary
endpoint was inpatient mortality rates among esophageal cancer
patients receiving enteral versus parenteral nutrition. Secondary
outcomes included length of hospital stay, overall treatment costs,
occurrences of pneumonia, rates of surgical interventions, complications such as esophageal perforation, instances of malnutrition,
constipation, hypoglycemia, fluid and electrolyte imbalances,
septic shock, acute kidney injury, and acute respiratory failure.
Covariates: Patients’ characteristics included age groups (<18-
35, 36-45, 46-64, >65 years), gender, race/ethnicity, household
income level, insurance status (Medicare, Medicaid, private and
uninsured), as well as certain comorbidities such as diabetes,
hypertension, hyperlipidemia, fluid, and electrolyte disorders.
Hospital-related characteristics included hospital bed size (small,
medium, large), location (rural-urban), teaching vs non-teaching
status, and hospital region (Northeast, Midwest, South, West).
The evaluation of comorbidity burden utilized the Elixhauser Comorbidity Index, a thoroughly validated metric relying on ICD-10-
CM codes. Designed for application in extensive administrative
datasets, this index serves the purpose of prognosticating both
mortality and the utilization of hospital resources.
Statistical analysis: Categorical data was presented as percentages. Continuous variables were described as mean values and
standard deviations. We used Pearson’s chi-square test or Fisher’s
exact test to compare outcomes between different groups for categorical variables. The student’s t-test was used for continuous
variables. Both univariate and multivariate analyses were conducted to identify the associations between nutrition methods and inhospital mortality, extended length of stay, total treatment cost,
and adverse outcomes. All statistical analyses were performed
using the software program Stata 17 (College Station, TX, USA).
The findings and outcomes of the statistical analyses conducted
using Stata 17 provided valuable insights into the research questions and hypotheses, contributing to the overall quality and rigor
of the study.
Results
A total of 28015 hospitalizations with esophageal cancer were
studied. Approximately 756(2.7%) received enteral nutrition, while 1064(3.8%) received parenteral nutrition.
A comparison of baseline patient characteristics revealed
an interesting disparity in insurance coverage between enteral
and parenteral nutrition groups. It is notable that patients on
enteral nutrition tended to have higher Medicare group representation compared to those on parenteral nutrition (69.4% vs
52.91%, P=0.03). Conversely, a larger proportion of patients receiving parenteral nutrition possessed private insurance (31.07%
vs. 17.91%, P=0.03) and Medicaid coverage (13.59% vs. 8.21%,
P=0.03), while uninsured patients were more prevalent in the enteral group (4.48% vs 2.4%, P=0.03).
A higher proportion of patients receiving parenteral nutrition
experienced fluid and electrolyte disorders (53.77% vs 43.07%,
P<0.001). A larger percentage of patients on parenteral nutrition were discharged to skilled nursing facilities (5.19% vs 0%,
P<0.001), while a higher proportion of enteral nutrition patients
were discharged to home with home health (66.92% vs 60.39%,
P<0.001). Smaller hospitals had fewer patients receiving parenteral nutrition compared to large hospitals (11.32% vs 22.63%,
P=0.001). Similarly, non-teaching hospitals had a higher percentage of patients on enteral nutrition compared to teaching hospitals (30.66% vs 15.09%, P<0.001) (Table 1).
Table 1: Comparison of baseline characteristics in esophageal can-
cer patients with enteral and parenteral nutrition.
|
Esophageal cancer
with enteral nutrition
|
Esophageal cancer
with parenteral nutrition
|
P-Value |
No. of patients |
756 |
1064 |
|
Patient characteristics |
|
|
|
Gender (%) |
|
|
P=0.5933 |
Male |
568 (75.18) |
803 (75.47) |
|
Female |
188 (24.82) |
261 (24.53) |
|
Age |
|
|
P=0.548 |
Mean age (SD) |
68.78 (11.55) |
66.55 (11.06) |
|
Age distribution (%) |
|
|
P=0.3433 |
18-35 |
0 (0) |
10 (0.94) |
|
36-45 |
17 (2.19) |
35 (3.3) |
|
46-64 |
237 (31.39) |
442 (41.51) |
|
>65 |
502 (66.42) |
577 (54.25) |
|
Race (%) |
|
|
P=0.6048 |
White |
594 (78.63) |
842 (79.1) |
|
Black |
110 (14.5) |
117 (10.95) |
|
Hispanic |
29 (3.82) |
74 (6.97) |
|
Other |
23 (3.05) |
32 (2.99) |
|
Median household income
national quartile for
patient zip code (%)
|
|
|
P=0.3529 |
$1-$49,999 |
258 (34.09) |
305 (28.71) |
|
$50,000-$64,999 |
206 (27.27) |
270 (25.36) |
|
$65,000-$85,999 |
172 (22.73) |
219 (20.57) |
|
>$86,000 |
120 (15.91) |
270 (25.36) |
|
Charlson comorbidity index
(%)
|
|
|
P<0.001 |
2 |
171 (22.63) |
226 (21.23) |
|
3 or more |
585 (77.37) |
838 (78.77) |
|
Insurance provider (%) |
|
|
P=0.0353 |
Medicare |
525 (69.4) |
563 (52.91) |
|
Medicaid |
62 (8.21) |
145 (13.59) |
|
Private |
135 (17.91) |
331 (31.07) |
|
Uninsured |
34 (4.48) |
26 (2.4) |
|
Comorbidities (%) |
|
|
|
Hypertension |
337 (44.53) |
462 (43.4) |
P=0.6561 |
Diabetes mellitus |
105 (13.87) |
201 (18.87) |
P=0.1524 |
Fluid & ectrolyte
disorders
|
326 (43.07) |
572 (53.77) |
P<0.001 |
Chronic kidney disease |
61 (8.03) |
105 (9.91) |
P=0.7254 |
ESRD |
11 (1.46) |
10 (0.94) |
P=0.4875 |
Hyperlipidemia |
210 (27.74) |
351 (33.02) |
P=0.1540 |
Smoking |
11 (1.46) |
5 (0.47) |
P=0.6342 |
Discharge disposition |
|
|
P<0.001 |
Home |
250 (33.04) |
366 (34.42) |
|
Home with home health |
506 (66.96) |
643 (60.39) |
|
Skilled nursing facility
|
0 (0) |
55 (5.19) |
|
Against medical advice |
0 (0) |
0 (0) |
|
Hospital characteristics (%)
|
|
|
|
Bed size of hospital
(STRATA)
|
|
|
P=0.0016 |
Small |
171 (22.63) |
120 (11.32) |
|
Medium |
232 (30.66) |
211 (19.81) |
|
Large |
353 (46.72) |
733 (68.87) |
|
Hospital location |
|
|
P=0.2124 |
Rural |
61 (8.03) |
45 (4.25) |
|
Urban |
695 (91.97) |
1019 (95.75) |
|
Hospital teaching status
|
|
|
P<0.001 |
Non-teaching hospital |
232 (30.66) |
161 (15.09) |
|
Teaching hospital |
524 (69.34) |
903 (84.91) |
|
Region of hospital |
|
|
P=0.7767 |
Northeast |
171 (22.63) |
226 (21.23) |
|
Midwest |
149 (19.71) |
241 (22.64) |
|
South |
315 (41.61) |
381 (35.85) |
|
West |
121 (16.06) |
216 (20.28) |
|
Table 2: Regression analysis for LOS and TOTCHG in esophageal cancer patients with enteral vs parenteral nutrition.
|
Esophageal cancer with
enteral nutrition
|
Esophageal cancer with
parenteral nutrition
|
Linear regression |
Coefficient |
95% CI |
P value |
Coefficient |
95% CI |
P value |
Length of hospitalization
(days)
|
Univariate regression |
4.46 |
(0.42-8.50) |
P=0.03 |
9.61 |
(7.15-12.07) |
P<0.001 |
Multivariate regression |
3.07 |
(1.23-4.92) |
P=0.001 |
9.07 |
(6.40-11.74) |
P<0.001 |
Total hospital cost (USD)
|
Univariate regression |
78100 |
(-6731-162932) |
P=0.071 |
122119 |
(78580-165657) |
P<0.001 |
Multivariate regression |
54953 |
(12595-97310) |
P=0.01 |
112093 |
(66905-157281) |
P<0.001 |
|
Mortality in esophageal
cancer patients with enteral
vs parenteral nutrition
|
Logistic regression |
Odds Ratio |
95 % CI |
P value |
Odds Ratio |
95% CI |
P value |
Mortality |
Unadjusted odds ratio |
0.73 |
(0.34-1.59) |
P=0.438 |
2 |
(1.28-3.07) |
P=0.002 |
Adjusted odds ratio |
0.56 |
(0.25-1.26) |
P=0.162 |
1.75 |
(1.08-2.84) |
P=0.023 |
LOS: Length of Stay, TOTCHG: Total Charges, USD: United States Dollar, CI: Confidence Interval.
After adjusting for the confounding variables, parenteral nutrition was determined to be an independent predictor of mortality
in cancer patients, whereas enteral nutrition was not associated
with higher mortality (OR 1.75, 95% CI: 1.08-2.84, P=0.023 vs OR
0.56, 95% CI: 0.25-1.26, P=0.162). Both modes of nutrition were
linked to increased length of stay, but patients receiving parenteral nutrition had significantly longer stays compared to those
on enteral nutrition (+9.07 days, 95% CI: 6.40-11.74, P<0.001
vs (+3.07 days 95% CI: 1.23-4.92, P=0.001). Both modes of nutrition were associated with high total hospitalization charges,
but patients with parenteral nutrition had a significantly more
pronounced increase in the total cost of treatment compared to
those on enteral nutrition (+112093 USD, 95% CI: 66905-157281,
P<0.001 vs (+54953 USD, 95% CI: 12595-97310, P=0.01) (Table 2).
Patients on enteral nutrition were less likely to have pneumonia compared to the parenteral nutrition group (OR 0.11, 95% CI:
0.02-0.76, P=0.025). Patients receiving parenteral nutrition had
higher odds of esophageal perforation (OR 3.51 95% CI: 1.71-
7.22, P=0.001), constipation (OR 1.61, 95% CI: 1.1-2.37, P=0.016),
diarrhea (OR 2.34, 95% CI: 1.14-4.79, P=0.021), acute kidney injury (OR 1.91, 95% CI: 1.33-2.74, P<0.001), ICU admission (OR
2.44,95% CI: 1.69-3.54 P<0.001), and acute respiratory failure (OR
1.82, 95% CI: 1.25-2.63, P=0.001) compared to those on enteral
nutrition. However, both forms of nutrition were linked to higher
odds of malnutrition (OR 2.25, 95% CI: 1.54-3.26, P<0.001 and OR
3.24, 95% CI: 2.31-4.54, P<0.001), fluid and electrolyte disorders
(OR 1.52, 95% CI: 1.07-2.16, P=0.019 & OR 2.12, 95% CI: 1.57-
2.84, P<0.001)) as well as septic shock (OR 2.85, 95% CI 1.31- 6.22,
P=0.008 and OR 3.27, 95% CI 1.80-5.93, P<0.001) (Table 3).
Table 3: Comparison of secondary outcomes in esophageal cancer with enteral and parenteral nutrition.
|
Esophageal cancer with
enteral nutrition
|
Esophageal cancer with
parenteral nutrition
|
Secondary outcomes |
Unadjusted OR (95% CI)
|
P value |
Adjusted OR (95% CI) |
P value |
Unadjusted OR (95% CI)
|
P value |
Adjusted OR (95% CI) |
P-value |
Pneumonia |
0.12 (.02-.87) |
P=0.036 |
0.11 (0.02-.76) |
P=0.025 |
1.77 (1.08- 2.91) |
P=0.023 |
1.43 (0.83- 2.49) |
P=0.195 |
Esophageal perforation |
1.45 (0.45-4.66) |
P=0.529 |
1.93 (0.60- 6.23) |
P=0.266 |
3.81 (1.93- 7.52) |
P<0.001 |
3.51 (1.71-7.22) |
P=0.001 |
Malnutrition |
2.68 (1.89- 3.79) |
P<0.001 |
2.25 (1.54- 3.26) |
P<0.001 |
3.50 (2.57- 4.76) |
P<0.001 |
3.24 (2.31- 4.54) |
P<0.001 |
Constipation |
1.18 (0.73- 1.92) |
P=0.492 |
1.23 (0.73- 2.06) |
P=0.425 |
1.57 (1.08- 2.27) |
P=0.016 |
1.61 (1.1- 2.37) |
P=0.016 |
Diarrhea |
-0.01 (-0.03-0.01) |
P=0.346 |
0.70 (0.17- 2.97) |
P=0.637 |
.025 (-0.003-.05) |
P=0.081 |
2.34 (1.14-4.79) |
P=0.021 |
Hypoglycemia |
1.55 (0.48-5.01) |
P=0.457 |
1.36 (0.42- 4.44) |
P=0.613 |
2.28 (0.97-5.31) |
P=0.056 |
2.21 (0.94- 5.17) |
P=0.066 |
Fluid and electrolyte
disorders
|
1.49 (1.07-2.07) |
P=0.017 |
1.52 (1.07-2.16) |
P=0.019 |
2.22 (1.70- 2.90) |
P<0.001 |
2.12 (1.57- 2.84) |
P<0.001 |
Septic shock |
3.60 (1.83- 7.03) |
P<0.001 |
2.85 (1.31- 6.22) |
P=0.008 |
3.94 (2.25- 6.90) |
P<0.001 |
3.27 (1.80- 5.93) |
P<0.001 |
Acute kidney injury |
1.47 (0.97-2.22) |
P=0.069 |
1.22 (0.77- 1.94) |
P=0.401 |
2.18 (1.59- 2.99) |
P<0.001 |
1.91 (1.33- 2.74) |
P<0.001 |
Intensive Care Unit (ICU)
|
1.70 (1.02-2.70) |
P=0.040 |
1.61 (0.95-2.71) |
P= 0.074 |
3.21 (2.28-4.51) |
P<0.001 |
2.44 (1.69-3.54) |
P<0.001 |
Acute respiratory failure
|
1.33 (0.82- 2.16) |
P=0.242 |
1.38 (0.83- 2.29) |
P=0.213 |
2.26 (1.62- 3.15) |
P<0.001 |
1.82 (1.25-2.63) |
P=0.001 |
Esophageal resection/surgery
|
0.82 (0.57- 1.20) |
P=0.328 |
1.09 (0.72-1.63) |
P= 0.685 |
1.11 (0.84- 1.47) |
P=0.442 |
1.05 (.77-1.44) |
P=0.741 |
OR: Odds Ratio.
Discussion
The current study addressed a clinical concern pertaining to
individuals diagnosed with esophageal cancer, namely the heightened risk of malnutrition and its correlative association with divergent modes of nutritional intervention. The study adopted a
rigorous analytical framework, analyzing adult discharges associated with esophageal cancer within the confines of 2019 to 2020,
utilizing data obtained from the National Inpatient Sample.
Our retrospective study found parenteral nutrition was determined to be an independent predictor of mortality in cancer patients, whereas enteral nutrition was not associated with higher
mortality. Both modes of nutrition were linked to increased
length of stay, but patients receiving parenteral nutrition had significantly longer stays compared to those on enteral nutrition. Both modes of nutrition were associated with high total hospitalization charges, but patients with parenteral nutrition had a significantly more pronounced increase in the total cost of treatment
compared to those on enteral nutrition. Furthermore, patients on
enteral nutrition were less likely to have pneumonia compared to
the parenteral nutrition group. Patients receiving parenteral nutrition had higher odds of esophageal perforation, constipation,
diarrhea, acute kidney injury, ICU admission, and acute respiratory failure compared to those on enteral nutrition. Both forms
of nutrition were linked to higher odds of malnutrition, fluid and
electrolyte disorders, as well as septic shock.
A literature review and meta-analysis of enteral versus parenteral nutrition in cancer patients showed that EN and PN are
considered equally effective in maintaining or improving nutritional status in cancer patients [6]. The review strongly supports the
recommendation that a baseline nutritional assessment should
be carried out by a healthcare professional expert in AN for all
cancer patients and the patient symptoms, performance status,
estimated life expectancy, and mainly, will or preferences have
to be evaluated and incorporated into the nutrition support plan
before the definitive choice of the route for delivering nutrients
is decided [7]. A decision-making process tailored to individual
patient needs—regardless of whether receiving or not anticancer
treatment for esophageal cancer—allows one to choose reasonably the optimal nutritional support strategy.
Another study evaluated clinical outcomes and hospitalization
cost between Early Enteral Nutrition (EEN) and Parenteral Nutrition (PN) after resection of esophageal cancer. The clinical factors
such as time to first fecal passage, postoperative albumin infusion, differences of serum albumin value, hospital stay, Systemic
Inflammatory Response Syndrome (SIRS) duration, complications,
initial hospitalization cost, and mortality were retrospectively
compared. The findings of this study concurred with our conducted research, adding further support to the robustness of our
conclusions. The study found pneumonia was significantly more
frequent in the PN group compared with the EEN group [8]. The
EEN group had a significantly shorter hospital stay, lower initial
hospitalization cost, earlier first fecal passage, and shorter duration of SIRS than PN group [8]. The percentage of patients having
any postoperative complication was much higher in the PN group
than the EEN group.
Previously, metabolic complications have been mentioned
throughout the literature in frail patients receiving parenteral nutrition [9]. Specifically, The European Society for Clinical Nutrition
and Metabolism Guidelines for Parenteral Nutrition in Geriatric
Patients state metabolic complications are more frequent in elderly patients. However, literature provides limited information
about metabolic complications in older patients receiving parenteral nutrition. Patients at Cooper University Hospital were assessed for acid-base disturbances, hepatic complications, hypercapnia, hyperchloremia, hyperglycemia, hypernatremia, hypertriglyceridemia, hypochloremia, hypoglycemia, hypokalemia, hypophosphatemia, and refeeding syndrome. The study found that
older hospitalized patients are more likely to develop a metabolic
complication during their PN course than younger patients [9].
Regarding acute kidney injury and parenteral nutrition, previous research analyzing current long-term total parenteral nutrition (TPN) patients (13 men, 20 women) aged 21 to 79 years
were prospectively studied to evaluate their change in glomerular
filtration rate since beginning TPN. Creatinine Clearance (CrCl)
from the subject’s initial home TPN clinic visit and at present
were estimated from standard formulas and compared. The study
ultimately described a profound decrease in renal function associated with long-term TPN, most of which is largely unexplained
[10]. Diarrhea and fatty liver disease have also been identified in
previous case reports and literature reviews with total parenteral
nutrition [11,12]. While mini reviews suggest multiple comorbidities and complications with enteral and parenteral nutrition in patients with esophageal cancer, there remains a dearth of current
case reports and findings on many of the associations we discovered through our retrospective study.
Additional complications have been addressed in literature reviews on the topic of nutrition and esophageal resection or esophagectomy. In esophagectomy, timing and type of postoperative
feeding remain a matter of debate. Total Parenteral Nutrition
(TPN) was found to be associated with severe septic complications
and Enteral Nutrition (EN) does not increase major complications.
Therefore, this review found early EN after esophagectomy is favored over TPN [13]. However, with enteral feeding tubes minor
complications occur frequently (13-38%) and in some cases this
can hamper recovery [13]. Based on experience in other types of
upper gastro-intestinal surgery, early start of oral feeding could
improve time to functional recovery after surgery. The total length
of stay was significantly shorter in four prospective studies (6-12
vs. 8-13 days) [13]. However, large randomized controlled trials
are lacking and the potential benefit of early oral feeding after
esophageal surgery remains unknown. EN is currently the optimal
feeding route after esophagectomy. TPN should only be used in
specific cases in which EN is contraindicated. Early initiation of
oral intake was found to be promising and could improve postoperative recovery. TPN after esophagectomy was also associated
with severe catheter-related complications, an increase in infectious complications and costs of this feeding route are relatively
high in contrast to EN [13].
Literature reviews have discussed that due to the severity of
complications associated with parenteral nutrition, many of which
were identified in our retrospective study, TPN is not considered
the preferred route of postoperative feeding. Early initiation of
parenteral nutrition does not improve recovery and is associated
with a higher incidence of septic complications [14]. Most trials
comparing EN and TPN after esophageal surgery found a reduction in severe complications and length of hospitalization in favor
of EN [15-17]. Therefore, the use of TPN after esophageal surgery
should be administered only if EN is not recommended.
Economic ramifications of the nutritional paradigms were
examined, revealing that patients reliant on parenteral nutrition
incurred significantly elevated total hospitalization charges in
comparison to their enteral nutrition counterparts. This finding
accentuates the considerable fiscal encumbrance entailed in the
adoption of parenteral nutrition.
Regardless of the reason for hospitalization, whether it was due
to surgical resection, complex chemotherapy or radiotherapeutic
interventions, complications of procedures, or acute illness, our
research findings align with prior studies in indicating that parenteral nutrition is associated with more adverse events in hospitalized esophageal cancer patients. However, the generalization
of our study provides deeper insight into the overall impact of
parenteral nutrition in this patient population and emphasizes the
importance of careful consideration and monitoring when implementing this form of nutritional support.
Our research aimed to ensure the accuracy and validity of the
data in this database, it is essential to acknowledge its limitations.
One limitation relates to the reliance on administrative data for
the NIS, which can lead to incorrect coding for diagnoses and procedures. Another significant shortcoming concerns the exclusion
criteria for patients not admitted or treated at non-HCUP hospitals
or those receiving outpatient care not captured by NIS. Moreover, while the large sample size provided by NIS aids in creating
strong statistical models, this extensive coverage may result in
biased prevalence and incidence estimates due to a lack of representation of smaller populations or rare events. Finally, beyond
issues with patient population selection biasing outcomes, measures such as readmission rates can also be affected since postdischarge follow-ups are not included in the data.
Conclusion
Our retrospective study highlights that both parenteral and
enteral nutrition are linked to increased hospitalization costs,
length of stays, and other in-hospital adverse outcomes. It is important to note that complications are more frequently observed
in parenteral nutrition, associated with an increased mortality risk
compared to enteral nutrition. Since esophageal cancer patients
face the highest risk of malnutrition and adverse effects, this work
is imperative in providing cancer patients with necessary information on the choices they have for artificial nutrition and expected
outcomes, timeframes, and costs associated with either parenteral or enteral nutrition.
References
- Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, & Arnold M. The global landscape of Esophageal squamous cell carcinoma and Esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: New estimates from GLOBOCAN 2020. Gastroenterology. 2022; 163(3): 649 58.e2. https://doi.org/10.1053/j.gastro.2022.05.054.
- Hoeppner J, & Kulemann B. Circulating Tumor Cells in Esophageal Cancer. Oncology research and treatment. 2017; 40(7-8): 417-422. https://doi.org/10.1159/000478863.
- World Cancer Research Fund International. Oesophageal cancer statistics.WCRF International. 2022. https://www.wcrf.org/cancertrends/oesophageal-cancer-statistics/.
- Zhang C, Hu LW, Qiang Y, Cong ZZ, Zheng C, Gu WF, Luo C, Xie K, Shen Y. Home enteral nutrition for patients with esophageal cancer undergoing esophagectomy: A systematic review and meta-analysis. Front Nutr. 2022; 9: 895422. doi: 10.3389/fnut.2022.895422. PMID: 35967793; PMCID: PMC9366554.
- Lewis SR, Schofield-Robinson OJ, Alderson P, & Smith AF. Enteral versus parenteral nutrition and enteral versus a combination of enteral and parenteral nutrition for adults in the intensive care unit. The Cochrane database of systematic reviews. 2018; 6(6). CD012276.https://doi.org/10.1002/14651858.CD012276.pub2.
- Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol. 2013; 87: 172-200.
- Cotogni P. Enteral versus parenteral nutrition in cancer patients: evidences and controversies. Annals Of Palliative Medicine. 2016; 5(1): 42-49. doi: 10.3978/j.issn.2224-5820.2016.01.05.
- Yu HM, Tang CW, Feng WM, Chen QQ, Xu YQ, & Bao Y. Early Enteral Nutrition Versus Parenteral Nutrition After Resection of Esophageal Cancer: a Retrospective Analysis. The Indian journal of surgery. 2017; 79(1): 13-18. https://doi.org/10.1007/s12262-015-1420-7.
- Solomon DM, Hollands JM, Pontiggia L, Delic JJ, & Bingham AL. Metabolic Complications Occur More Frequently in Older Patients Receiving Parenteral Nutrition. Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition. 2020; 35(4): 627-633. https://doi.org/10.1002/ncp.10499.
- Buchman AL, Moukarzel A, Ament ME, Gornbein J, Goodson B, Carlson C, & Hawkins RA. Serious renal impairment is associated with long-term parenteral nutrition. JPEN. Journal of parenteral and enteral nutrition. 1993; 17(5): 438-444. https://doi.org/10.1177/0148607193017005438.
- Connon JJ. Diarrhea possibly caused by total parenteral nutrition. The New England journal of medicine. 1979; 301(5): 273-274. https://doi.org/10.1056/NEJM197908023010519.
- Freund U. Liver disease after TPN. Gastroenterology. 1982; 82(1): 164-165.
- Berkelmans G, van Workum F, Weijs T, Nieuwenhuijzen G, Ruurda J, Kouwenhoven E, van Det M, Rosman C, Hillegersberg R, & Luyer M. The feeding route after esophagectomy: a review of literature. Journal Of Thoracic Disease. 2017; 9(8): 785-791. doi:10.21037/jtd.2017.03.152.
- Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011; 365: 506-17.
- Baigrie RJ, Devitt PG, Watkin DS. Enteral versus parenteral nutrition after oesophagogastric surgery: a prospective randomized comparison. Aust N Z J Surg. 1996; 66: 668-70.
- Gabor S, Renner H, Matzi V, et al. Early enteral feeding compared with parenteral nutrition after oesophageal or oesophagogastric resection and reconstruction. Br J Nutr. 2005; 93: 509-13.
- Fujita T, Daiko H, Nishimura M. Early enteral nutrition reduces the rate of life-threatening complications after thoracic esophagectomy in patients with esophageal cancer. Eur Surg Res. 2012; 48: 79-84.